Clinically, YTHDF1 is a potential prognostic biomarker, and the ability of STM2457 to reverse YTHDF1-mediated phenotypes supports targeting m6A-dependent pathways in NPC. Here, YTHDF1 is linked to nasopharyngeal carcinoma.